Growth beats guide, but the rally has run to ATH on margin headwinds and capex caution
Sai delivered 22.5% revenue growth (beating 15–20% guidance) and 28.3% OPM (in-line), validating the integrated CRDMO strategy. But raw material cost inflation is eating margins, 225 KL capacity slipped 6 months, and the stock is at all-time high with overbought technicals—the rally deserves skepticism.
Sai Life Sciences delivered a quarter that passes the headline test—22.5% revenue growth beats the 15–20% long-term guidance, OPM is stable at 28.3% (within 28–30% range), and PAT rose 17.3% YoY. The integrated CRDMO strategy is being validated: two major pharma partnerships are now live, biotech enquiries are picking up, and headcount is scaling (+1,200 in first half to ~4,400). But the earnings quality is muddier. Raw material costs from Middle East supply constraints are rising (solvents, chemicals), and the company acknowledged these will impact near-term margins until full recovery through customer contracts is realized. A 6-month push-out on the 225 KL CDMO capacity (from Q4 FY27 to Q3 FY28) signals execution caution. And the stock is at all-time high with RSI at 80.5 (overbought), while FII have trimmed 1.52 percentage points—the smart money is selling into the rally.
22.5%
YoY; beats 15–20% guide
28.3%
Flat YoY, within 28–30% range
17.3%
YoY; steady, below revenue
₹621 Cr
On track for ₹1,100–1,300 Cr FY27
Where the margin pressure is hiding
OPM looks stable at 28.3% YoY, and the call data confirms this is within guidance. But the call also flagged that Middle East supply constraints have driven up solvents and chemicals costs, and while the company is working customer contracts to recover these, the full pass-through hasn't landed in this quarter's PAT yet. That means Q3 is the proving ground: if recovery mechanisms work, margins hold; if they don't, OPM compresses. The company is hedging: it says costs are "modest" and "being recovered," but analysts pressed hard on the timeline. Management deferred specifics. For a holder, this is a near-term lever on earnings quality.
What changed on this call
Integrated CRDMO validated: 2 major pharma partnerships now live (discovery→dev→commercial), up from 'potential' prior
Biotech funding cycle returning: Uptick in enquiries observed; recovery expected 18–24 months out
225 KL CDMO capacity pushed 6 months: Q4 FY27 → Q3 FY28 per customer priorities
Raw material inflation: Middle East situation spiking solvents/chemicals; recovery in progress
Headcount ramp: +1,200 in first half to ~4,400, validating integrated model scaling
The bull-bear ledger
Growth 22.5% beats 15–20% guidance; CRO +28%, CDMO +20%
Integrated CRDMO strategy validated: 2 pharma programs live, 5–7 evaluating
Biotech recovery beginning; enquiries uptick, expected 18–24 month ramp
Long-term tailwinds intact: China controls (COINS Act), India CDMO positioning
Largest customer ~12% of revenue; top 10 ~40–50% (concentration risk)
Raw material costs rising; recovery mechanisms not yet fully realized
225 KL capacity delayed 6 months; capex execution flexibility signals caution
Partnership revenue undefined: 2 programs live, wallet share and ramp absent
Stock at all-time high, RSI 80.5 (overbought); FII trimming 1.52pp
Risks, ranked by how much they should concern a holder
Valuation and momentum at all-time high
HighStock at ₹1918.6, all-time high, RSI 80.5 (overbought). FII reduced 1.52pp despite bullish fundamentals—smart money skeptical of valuation at the peak. Disappointment on margin recovery or partnership monetization triggers correction.
Customer concentration and pharma outsourcing consolidation
MediumLargest customer ~12%, top 10 ~40–50%. Pharma outsourcing is consolidating. If a top customer exits, revenue impact is material. Integrated model aims to dilute risk but is early-stage and unproven.
Raw material cost pass-through delayed
MediumMiddle East crisis elevated solvents/chemicals costs. Q2 OPM stable, but full recovery not yet in PAT. If Q3 shows margin compression despite recovery efforts, earnings quality deteriorates.
Partnership monetization vague and slow
Medium2 pharma programs live, but revenue ramp undefined. Competitors take multi-year ramps. If Sai's ramp is slower than expected or wallet share dilutes, growth outlook softens and margins compress.
Capex execution delays
Low225 KL pushed 6 months. First phase (Bidar) on track. Slippage within broader plan, but flexibility suggests caution on customer visibility. Full-year capex reaffirmed; near-term risk low.
How the street is positioned
The stock rallied hard to all-time high, up 144.77% from the 52-week low, and sits well above all key moving averages (SMA20 ₹1539.83, SMA50 ₹1551.94, SMA200 ₹1227.6). Volume is increasing, technicals look extended (RSI 80.5 = overbought). The puzzle: despite the bullish call and growth beat, FII reduced their holding by 1.52 percentage points to 19.65%, while DII added 1.17pp to 32.71%. This is classic momentum-chasing by retail/domestic investors bumping into institutional skepticism. FII at 19.65% is near multi-year lows. The FII outflow despite bullish fundamentals signals the smart money sees valuation risk at all-time highs. A pullback would likely trigger FII re-entry; support is the 50-day and 200-day moving averages.
The debate
Bull case: Sai is the go-to India CRDMO for global pharma. 22.5% growth beats guidance; 2 major partnerships live and validate the integrated model. Biotech recovery is beginning. China export controls and India positioning create structural tailwinds. CRO +28% for 8 quarters. Guidance for 15–20% long-term growth is conservative, likely under-delivery. Hold for re-rating on partnership scale.
Bear case: Stock at all-time high with overbought technicals (RSI 80.5), FII exiting despite bullish headlines. Valuation assumes partnership monetization at scale, but 2 programs are early-stage and competitors take multi-year ramps. Margin recovery from raw material costs is not guaranteed. Largest customer ~12%, concentration real. Capex delays signal execution caution. Integrated model unproven on wallet share. Risk/reward skewed against you at ATH.
The honest read: This is a good company with a validated strategy (2 pharma programs live) growing faster than guidance (22.5% vs. 15–20%), but the stock has run to all-time high on momentum, detached from clarity on margin recovery or partnership monetization. The quarter proved the integrated model works; it did not prove scale or monetization. Hold if you own it; wait for pullback to buy. Q3 will tell if margins recover (OPM recovery despite raw materials), if partnership commentary improves (even unquantified), and if capex tracks (225 KL timeline toward Q3 FY28). If those land, re-rating higher is possible. If not, downside is real from ATH. Prefer a pullback entry or hold-at-levels for existing positions.
1 · Q3 FY27 margin recovery
The test for raw material cost pass-through. If OPM recovers to 28.3%+ despite Middle East solvents inflation, margin recovery story is intact. If compressed, cost inflation is stickier than expected. Single most important metric for Q3.
2 · Partnership revenue ramp
2nd pharma integrated program expected 'fully functional' in Q3 FY28. Even if unquantified, qualitative color on customer comfort, wallet share, and trajectory validates the business model. Vague commentary keeps valuation at risk.
3 · 225 KL commissioning progress
On track for Q3 FY28? Further delays signal execution caution. On-time delivery confirms capex discipline and customer confidence.
Sai delivered a solid quarter—growth beats, strategy validated, partnerships live. But earnings quality faces near-term headwinds (raw material costs), execution caution is evident (225 KL delayed), and valuation at all-time high is vulnerable. The honest read is steady execution, not a step-change. Watch Q3 OPM: that's the lever on margin recovery, and it will tell if the rally is justified or stretched. For holders: no urgency to exit, but wait for clarity. For prospective buyers: wait for pullback or Q3 proof. The 50-day moving average (₹1539.83) is key support; a break below signals momentum has fully reversed. The number to track is organic margin recovery—not the topline beat.
Growth beats guide, partnerships validate strategy; capex delays moderate
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered 22.5% growth vs guided 15–20% long-term; capex reaffirmed ₹1,100–1,300 Cr but 225 KL moved 6 months.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Sai delivered a strong Q2 (22.5% YoY growth, 28.3% OPM) that beats its 15–20% long-term guidance and validates the integrated CRDMO strategy with 2 major pharma partnerships now live. However, a 6-month delay in the 225 KL capacity push-out, acknowledged customer concentration risk (~12% largest customer), and raw material cost pressure from Middle East supply chains create near-term execution uncertainty. Growth beats guidance but capex timeline slippage and investor pushback on partnership monetization warrant cautious positioning.
₹658.6 Cr
Revenue · +22.5% YoY₹98.3 Cr
Reported PAT · +17.3% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Earnings quality
What changed since the last call
225 KL capacity timeline
DowngradePushed from Q4 FY27 to Q3 FY28; mgmt cited customer priorities + capacity optimization. First phase (Bidar, 220 KL) remains on track.
Integrated CRDMO traction
Upgrade2 major pharmas now live on full-service discovery→dev→commercial; prior call mentioned 'potential'; now in validation phase.
Biotech funding cycle
UpgradeUptick in biotech enquiries observed; mgmt expects cycle recovery in 18-24 mo, unlocking discovery upside.
Raw material cost inflation
DowngradeMiddle East situation driving solvents/chemicals cost; being recovered via contracts, but short-term margin headwind until full pass-through.
FY27 capex envelope
NeutralMaintained ₹1,100–1,300 Cr; H1 spend ₹621 Cr on track for full-year guide.
The Q&A
Analysts pressed hard on customer concentration (Sajal Kapoor, Nishant Goyal), partnership monetization timeline (Amit Yadav, Dhawal Khut), and capex multi-year guidance (Roni Naik). Management acknowledged concentration, cited senior-level relationships as moat, and deferred revenue visibility ('no guidance'). Tone was confident but carefully hedged on specifics.
CRO growth momentum — Amey Chalke, JM
AnsweredIntegrated discovery capability (chemistry + DMPK + biology) expanded customer scope. Pharma presence grew from ~0% to 40% of CRO split. Added ~4,400 headcount by Sept FY27 to support scale.
NCE molecule count — Sidharth Negandhi, CWC
AnsweredCorrect. Added 3 molecules total this quarter; one moved late-phase→commercial, one exited (became less active). Net 34 confirmed.
Capacity utilization — Sidharth Negandhi, CWC
AnsweredYes, we consider 70–75% 'fully utilized' for plant economics. Taking 24–36 mo advance planning for pharmaceutical build. No commitment on any plant until customer visibility.
AI impact on discovery — Amit Yadav, KJMC
AnsweredAI won't reduce headcount or billable FTE. Better tools support optimization but don't change fundamental end-to-end model. Proof-of-concept from pharmas shows more molecules tested, not fewer labs.
Capex funding plan — Roni Naik, Arete
AnsweredLeverage is comfortable at this point. We will use internal + external if needed. No commitment on any plant until fully locked-in.
Integrated partnership revenue — Amit Yadav, KJMC
PartialWe don't give guidance in that count. Scope will expand over time as customer comfort builds. Integrated CRDMOs like WuXi, Pharmaron have multi-year ramp; ours will too.
Customer concentration — Sajal Kapoor, Antifragile Thinking
PartialRelationships are senior-level and company-level, not individual. Turnaround at Sai is extremely low. Pharma companies bet on the company, not one person.
Supplier concentration — Sidharth Negandhi, CWC
AnsweredIntegrated model means we do 5–7 different services per customer. Concentration per product is diluted. Top 10 customers diversify risk.
225 KL delay — Rahul Jeewani, IIFL
AnsweredSome large pharma customer needs took priority. We re-sequenced projects. Still within broader capex plan. 220 KL Bidar first phase on track.
H1/H2 split — Rahul Jeewani, IIFL
PartialWithout numbers, visibility good and expect stronger quarter. Anything more, I'll guide you to H2, which I would like to avoid.
GLP-1 and new modalities — Alankar Garude, Kotak Equities
AnsweredWe are adding manufacturing capacity at new sites. GLP-1 is via manufacturing partnerships, not discovery. Technology is changing; plants evolve with it.
Pharma partner universe — Dhawal Khut, Jefferies
AnsweredRight now, 2 live. 5–7 evaluating/in conversation. No timeline; contract negotiations always move slow. Depends on cycles, not guarantees.
Guidance
Long-term growth 15–20% YoY
HighMaintained from prior call; Q2 delivery 22.5% exceeds this, validating underlying strength.
H2 FY27 stronger than H1
MediumH1 actual 17% YoY; Q2 at 22.5% supports this trajectory. No numeric target for H2.
EBITDA margins 28–30%
HighQ2 OPM 28.3%, H1 EBITDA 28% per call. Within range; raw material cost pressure being managed.
FY27 capex ₹1,100–1,300 Cr
HighH1 spent ₹621 Cr (₹358 Cr in Q2); on track. Reaffirmed in call; 225 KL delay doesn't reduce amount, just timeline.
Risks the call surfaced
Customer concentration
MediumLargest customer ~12% of revenue; top 10 constitute ~40–50%. Pharma outsourcing concentrates on few vendors; customer switching costs low.
Capex execution
Low225 KL CDMO capacity moved from Q4 FY27 to Q3 FY28 (6-month delay). New greenfield sites (Telangana) add execution complexity.
Raw material inflation
MediumMiddle East supply constraints driving solvents/chemicals costs up. Recovery mechanisms via customer contracts in progress; short-term margin headwind.
Partnership monetization
MediumIntegrated CRDMO partnerships with pharma are early-stage (2 live, 5–7 evaluating). Revenue visibility absent; ramp timelines unclear. Competitor WuXi, Pharmaron have multi-year ramps.
Regulatory / geopolitical
LowUS COINS Act and China Ministry controls on biotech exports create structural opportunity for India CDMOs, but also potential supply-chain disruption if local regulations tighten.
Management
Score 7/10. Transparent on operational metrics (growth, EBITDA, capex spend). Cautious on forward claims (no partnership revenue guidance, capex multi-year targets). Clear on business mechanics (integrated CRDMO model, capacity roadmap). Delivered 22.5% growth beating 15–20% long-term guide; 28.3% OPM within 28–30% range. Capex on track (₹621 Cr H1 vs ₹1,100–1,300 FY27 plan). One 6-month timeline slip (225 KL) managed within broader priorities.
1 · Q3 FY28
225 KL CDMO capacity commissioned; 2nd integrated partnership revenue ramp
2 · Q4 FY27
Telangana facility groundbreak; new modality R&D (peptide, bioconjugation, ADC) near-complete
3 · H2 FY27
Second large pharma integrated program expected fully functional; biotech funding cycle tailwind amplifies discovery demand
Growth beats guidance but capex timeline slippage and investor pushback on partnership monetization warrant cautious positioning.
Sai Life Sciences Q2 FY27: consolidated revenue +23% YoY to ₹659 Cr, PAT lags at +17%
PAT +17.26% YoY · revenue +22.54% · margins compressing
₹658.59 Cr
+22.54% YoY
₹98.32 Cr
+17.26% YoY
14.84%
-0.3pp YoY
₹4.63
Sai Life Sciences' consolidated Q2 FY27 revenue rose 22.5% YoY (18.8% QoQ) to ₹658.6 Cr, matching the ₹659 Cr management flagged in its press release, while consolidated PAT grew a slower 17.3% YoY (34.2% QoQ) to ₹98.3 Cr — profit growth trailed revenue growth, the primary signal this quarter despite a strong topline. The YoY revenue growth sits above management's long-term 15-20% guided range from the prior concall, so on guidance the print is a beat; no verifiable Street consensus specifically for Q2 FY27 PAT/revenue turned up in search, so vs-Street is marked unknown rather than assumed. Standalone tracked closely (revenue ₹647.1 Cr, PAT ₹96.0 Cr, both within ~2% of consolidated), so there is no material standalone/consolidated divergence to flag.
Q2 FY-2027 vs prior quarters
The margin picture is two-sided. Operating (EBITDA) margin expanded to 28.3% from 27.1% a year ago and 26.7% last quarter — inside management's guided 28-30% band and evidence of genuine operating leverage as revenue scaled. But net margin compressed to 14.8% of total income from 15.2% a year ago (it did expand sequentially from 13.1%), because depreciation (₹48.1 Cr, +21% YoY) and finance costs (₹10.9 Cr, +17% YoY) grew faster than EBITDA as the company's capex ramp — ₹561 Cr of PP&E/intangible purchases in H1 FY27 alone, already 43-51% of the full-year ₹1,100-1,300 Cr guided capex band — puts more assets and debt on the books ahead of revenue contribution.
The stock went into the print at ₹1,757.9, up 12.6% over the past month of trading.
For context: revenue is at a 6-quarter high.
Long-term revenue growth 15–20% and EBITDA margins 28–30% maintained. FY27 capex ₹1,100–1,300 Cr (unchanged). H2 FY27 expected stronger than H1 due to capacity ramp (Q2/Q3 online); formulation facility ~6 months away.
— This quarter: beat
Management's own framing was unambiguously bullish: the press release called it 'a strong quarter' with 'continued business momentum' and customer engagements 'evolving from individual projects into larger, more strategic relationships.' The revenue number backs that up — growth accelerated versus both the year-ago quarter (+22.5%) and the immediately preceding one (+18.8%) — but the bottom line scaling more slowly is the counterpoint the headline omits. Alongside the results, the board appointed three senior management personnel (HR, Quality & Regulatory Affairs, and Corporate Communications) effective 5 November 2026; none of these are financially material to the quarter. No exceptional items were booked in either the current or year-ago quarter, so the YoY comparison needs no adjustment.
W1
Management guided H2 FY27 stronger than H1 as Q2/Q3 capacity comes online and the formulation facility (~6 months away per the prior concall) completes — watch H2 revenue acceleration against H1's ₹1,212.9 Cr consolidated revenue.
W2
FY27 capex guided at ₹1,100-1,300 Cr; ₹561 Cr already spent in H1 — watch whether H2 capex, and the resulting depreciation/finance-cost growth, stays within that band without further compressing net margin.
W3
Revenue growth this quarter (22.5% YoY) ran above the 15-20% long-term guidance management has maintained — watch whether the next earnings call reiterates or raises that band.
No exceptional items in the current or year-ago quarter (FY26's full-year ₹80.01mn labour-code exceptional item is unrelated to these columns); standalone and consolidated are within ~2% of each other; two subsidiaries (₹159.2 Cr assets) were reviewed by other auditors per the consolidated review report.